First human test of experimental COVID-19 inflammation drug
NCT ID NCT04622332
Summary
This completed early-stage study tested whether an experimental drug called SIR1-365 is safe for hospitalized patients with severe COVID-19. Researchers enrolled 45 adults to receive either the drug or a placebo for 14 days, monitoring side effects and whether it helped reduce inflammation or improve breathing. The main goal was to check safety, while also looking at whether patients needed less oxygen support.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aga Khan University Hospital
Karachi, Sindh, 74800, Pakistan
-
Baptist Medical Center
Jackson, Mississippi, 39202, United States
-
Dow University Hospital, Ojha Karachi
Karachi, Sindh, 74200, Pakistan
-
Hospital Civil Fray Antonio Alcalde
Guadalajara, Jalisco, 14050, Mexico
-
Hospital Universitario "Dr. José Eleuterio González"
Monterrey, Nuevo León, 64460, Mexico
-
Media Sur - Medica Sur Tlalpan
Tlalpan, Mexico City, 14050, Mexico
-
OSF St. Francis Medical Center
Peoria, Illinois, 61637, United States
-
Sindh Infectious Disease Hospital
Karachi, Sindh, 74200, Pakistan
-
Triple O Research Institute
West Palm Beach, Florida, 33407, United States
Conditions
Explore the condition pages connected to this study.